NASDAQ$MREO
Mereo Biopha-Adr · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Mereo BioPharma reported Q1 2026 net loss of $2.8M.
For the quarter ended March 31, 2026, Mereo BioPharma reported a net loss of approximately $2.8 million versus $1.7 million a year ago as rare-disease programs progress.
- Net loss $2.8M.
- Rare disease pipeline.
- Lower burn than larger peers.
- Partnership potential on assets.
Headline financials
Revenue & EPS history
Mereo Biopha-Adr · Revenue · Quarterly
$0
Forward guidance
Milestone payments and partnerships could fund operations.
Tailwinds
- Contained quarterly loss.
- Multiple orphan programs.
Headwinds
- No product revenue disclosed.
- Dependent on external funding.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2026
+3.4%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+18.4%
Avg return
30 days after
69%
9 / 13 earnings
Positive
+11.9%
Q4 2023
Best reaction
-6.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.1% | +0.9% | +31.7% | |
| Q4 2025 | +4.6% | -4.5% | -4.3% | |
| Q3 2025 | +6.3% | +0.6% | +27.1% | |
| Q2 2025 | +9.4% | +14.5% | +19.7% | |
| Q1 2025 | +1.3% | -2.2% | +25.3% | |
| Q4 2024 | -3.6% | -11.6% | +15.6% | |
| Q3 2024 | -5.4% | -17.5% | -12.9% | |
| Q3 2023 | -5.4% | -17.5% | -12.9% | |
| Q2 2024 | +6.2% | +16.4% | +18.0% | |
| Q1 2023 | +10.5% | +10.1% | +43.6% | |
| Q1 2024 | +10.5% | +10.1% | +43.6% | |
| Q4 2023 | +11.9% | +15.6% | -7.1% | |
| Q4 2022 | -6.1% | -10.3% | +52.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro